We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+20.96%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$776M
AUM Growth
+$47.7M
Cap. Flow
-$46.2M
Cap. Flow %
-5.95%
Top 10 Hldgs %
74.59%
Holding
30
New
4
Increased
13
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$23.8M
2
AKRX
Akorn Inc
AKRX
+$19.7M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$12.9M
4
TVTX icon
Travere Therapeutics
TVTX
+$10.5M
5
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$10.1M

Top Sells

Rank Stock Value
1
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$47.9M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$44.6M
3
HMSY
HMS Holdings Corp.
HMSY
+$17.2M
4
RLYP
RELYPSA INC COM
RLYP
+$13.9M
5
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 71.6%
2 Industrials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENTA icon
1
Enanta Pharmaceuticals
ENTA
$378M
$86.2M 11.11%
1,696,147
+97,038
+6% +$4.34M
UTHR icon
2
United Therapeutics
UTHR
$26.2B
$85.5M 11.01%
660,186
-101,576
-13% -$13.1M
CSII
3
DELISTED
Cardiovascular Systems, Inc.
CSII
$64.2M 8.27%
2,135,200
+192,146
+10% +$5.49M
ANIP icon
4
ANI Pharmaceuticals
ANIP
$1.83B
$61.5M 7.92%
1,090,067
+540,240
+98% +$23.8M
AKRX
5
DELISTED
Akorn Inc
AKRX
$60.9M 7.85%
1,683,485
+510,000
+43% +$19.7M
INSY
6
DELISTED
Insys Therapeutics, Inc.
INSY
$52.9M 6.81%
2,508,494
+268,660
+12% +$5.31M
ANAC
7
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$47.4M 6.11%
1,469,690
+431,137
+42% +$12.9M
ABBV icon
8
AbbVie
ABBV
$455B
$45M 5.8%
687,900
+108,800
+19% +$6.86M
OFIX icon
9
Orthofix Medical
OFIX
$477M
$43.2M 5.56%
1,436,495
– –
PTX
10
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$32.2M 4.15%
342,779
-1,535
-0.4% -$146K
TVTX icon
11
Travere Therapeutics
TVTX
$5.33B
$31.2M 4.02%
2,551,535
+1,012,076
+66% +$10.5M
HPTX
12
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$30M 3.87%
1,251,353
-11,681
-0.9% -$263K
OSIR
13
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$26.8M 3.45%
1,674,561
+95,000
+6% +$1.27M
TVTY
14
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$26.2M 3.37%
1,316,493
+618,303
+89% +$10.1M
DSCI
15
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$15.2M 1.96%
1,632,627
+112,223
+7% +$976K
ADMA icon
16
ADMA Biologics
ADMA
$2.01B
$9.8M 1.26%
+877,407
New +$10M
HSTM icon
17
HealthStream
HSTM
$824M
$9.46M 1.22%
321,026
+147,193
+85% +$4.18M
PLX icon
18
Protalix BioTherapeutics
PLX
$183M
$9.34M 1.2%
507,734
+5,000
+1% +$107K
EVDY
19
DELISTED
Everyday Health, Inc.
EVDY
$9.34M 1.2%
+633,150
New +$8.44M
OPCH icon
20
Option Care Health
OPCH
$3.36B
$8.23M 1.06%
294,286
-494,202
-63% -$12.3M
VCEL icon
21
Vericel Corp
VCEL
$2.43B
$7.15M 0.92%
2,352,940
– –
HMSY
22
DELISTED
HMS Holdings Corp.
HMSY
$6.33M 0.81%
299,246
-823,880
-73% -$17.2M
LCTX icon
23
Lineage Cell Therapeutics
LCTX
$277M
$5.98M 0.77%
+1,985,579
New +$5.37M
MSLI
24
DELISTED
Merus Labs International Inc.
MSLI
$2.25M 0.29%
+1,360,214
New +$1.98M
TARO
25
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
– –
-311,234
Closed -$47.9M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Consonance Capital Management held 30 positions worth $776M, up 6.6% from $729M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Consonance Capital Management withdrew a net $46.2M in Q4 2014, closing 6 positions and reducing 5 holdings. Its most notable exit was Taro Pharmaceutical Industries Ltd., an estimated $47.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 68% a quarter earlier, followed by Industrials.

Against the trend, Consonance Capital Management opened a new position in ADMA Biologics worth $9.8M.

  • Consonance Capital Management's largest Q4 2014 buy was ADMA Biologics: 877,407 shares worth $9.8M.
  • Consonance Capital Management added most to ANI Pharmaceuticals in Q4 2014, an estimated $23.8M increase.
  • Consonance Capital Management's biggest Q4 2014 reduction was HMS Holdings Corp., cutting an estimated $17.2M.
  • Consonance Capital Management fully exited Taro Pharmaceutical Industries Ltd. in Q4 2014, selling an estimated $47.9M.
  • Consonance Capital Management's ten largest holdings make up 75% of its $776M portfolio in Q4 2014.
  • Consonance Capital Management opened 4 new positions and closed 6 in Q4 2014.
  • Consonance Capital Management's portfolio value rose 6.6% quarter-over-quarter to $776M.

Based on Consonance Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.